Status:
COMPLETED
The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment
Lead Sponsor:
Qilu Hospital of Shandong University
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
16-90 years
Phase:
PHASE4
Brief Summary
This study is designed to observed prospectively the efficacy and safety of 6 months treatment of iguratimod alone, or with methotrexate (MTX), hydroxychloroquine (HCQ) and prednisone step by step on ...
Detailed Description
This study will enroll 200 cases of rheumatoid arthritis (RA) and early rheumatoid arthritis (ERA) patients in China, who are naïve or shown insufficiency response or intolerance to DMARDs. The partic...
Eligibility Criteria
Inclusion
- RA: Patients diagnosed based on 1987 ACR classification criteria for rheumatoid arthritis(RA);
- ERA: Subjects diagnosed by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR); or by 2012 Chinese classification criteria of early rheumatoid arthritis (ERA), and not match the 1987 ACR criteria for RA.
- Age ≥16 years;
- Extra-articular manifestations (such as pulmonary fibrosis, proteinuria, leukopenia and peripheral neuropathy ) of RA patients are stable or no significant progress;
- Patients can be naïve to any DMARDs, or relapse due to DMARDs drug suspended;
- Patients have a history of using csDMARDs including csDMARDs（methotrexate，leflunomide, hydroxychloroquine, sulfasalazine, tacrolimus) , any biologic DMARDs（TNFi，tocilizumab or Tofacitinib），glucocorticoid (prednisone，methylprednisolone) or Chinese traditional Medicine（including tripterygium Glycosides, sinomenine）for 3 months, but couldn't achieve clinical remission or intolerance；
Exclusion
- Patients with acute or chronic infections such as active bacterial, viral, fungal, tuberculosis infection or active hepatitis B;
- Platelet counts(PLT) \<80 x 10\^9 / L, or white blood cell (WBC) \<3 x 10\^9 / L;
- Propionate acid aminotransferase (ALT) or aspartate aminotransferase (AST) is two times higher than the upper limit of normal;
- Renal insufficiency: serum Cr ≥ 176 umol / L;
- Pregnant or nursing women (breastfeeding) ；
- Patients has a history of malignancy (cure time in less than 5 years);
- Patients with severe or poorly controlled hypertension, diabetes or cardiac dysfunction;
- Other comorbidities that cannot be treated with immune suppressants. In addition, once patients experience severe adverse drug reactions、ineffective treatment or rapid progression of rheumatoid arthritis, then quit this research.
Key Trial Info
Start Date :
January 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2023
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03855007
Start Date
January 1 2016
End Date
October 31 2023
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital
Jinan, Shandong, China, 250012